Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03043547

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies — NALIRICC  

Cholangiocarcinoma Non-resectable Clinical Trial

Official title:
A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Clinical Trial Summary

is an open label, randomized, multicenter phase II trial

Clinical Trial Description

The primary objective is to assess the efficacy of nal-IRI in gemcitabine pre-treated patients with advanced, unresectable and metastatic cholangio- and gallbladder carcinoma eligible for treatments after failure to respond to a gemcitabine-based treatment ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03043547
Study type Interventional
Source AIO-Studien-gGmbH
Contact
Status Completed
Phase Phase 2
Start date October 24, 2017
Completion date March 8, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03267940 - Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Phase 1
Active, not recruiting NCT06081829 - A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Phase 2
Completed NCT03473574 - Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients Phase 2
Completed NCT03377179 - A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma Phase 2
Recruiting NCT06192797 - Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma Phase 2
Terminated NCT02166190 - RFA RCT for Pancreatic or Bile Duct Cancer N/A
Recruiting NCT03364530 - Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma Phase 2
Recruiting NCT05978609 - Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer Phase 2
Recruiting NCT05655949 - Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Phase 2
Recruiting NCT06194695 - DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Recruiting NCT06192784 - Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT04860154 - Photodynamic Therapy for Cholangiocarcinoma N/A
Available NCT03414489 - Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)